Shares of Intuitive Surgical (NSDQ:ISRG) hit an all-time high yesterday of $529.70 and beat it today, as investors sent the shares to $531.35 apiece this morning.
The spikes followed an upgrade by analysts at Lazard Capital, who raised their price target on the stock to $575 from $525 and reinforced their “buy” rating.
The new slate of directors for Olympus Corp. (TYO:7733) is already drawing fire from foreign investors in the endoscopy giant, after its entire board resigned en masse over a $1.7 billion accounting scandal that’s slashed its valuation by about 50% since October.
Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
Shares of Smith & Nephew (NYSE:SNN) slipped initially but have regained some of their value since more talk of a possible buyout surfaced in the U.K. last week.
The British orthopedics giant is up 2.7 percent on The Street today to $43.94 after flirting with a 52-week low Friday, Nov. 25. The stock has fared even worse in its home country following an "uninspiring" meeting with analysts last week.
Zimmer Holdings (NYSE:ZMH) shares are down this morning in early trading after the orthopedics giant lowered its sales and earnings guidance for 2011 – despite beating analysts’ expectations with its third-quarter earnings.
Warsaw, Ind.-based Zimmer said third-quarter profits were $192 million, or $1.01 per share, on sales of $1.03 billion for the three months ended Sept. 30, up 5.2 percent and 6.9 percent, respectively, compared with the same period last year.
Advanced Cell Technology (OTC:ACTC) appointed MIT professor and bioengineering legend Bob Langer to its board of directors, tapping him to lead its science advisory committee.
Langer has authored more than 1,100 journal articles, has more than 800 issued and pending patents and won the 2011 Warren Alpert Foundation Prize for bioengineering pioneers thanks to his work in drug delivery and tissue engineering.